Replies to post #243142 on Biotech Values

[vinmantoo]

Reminds me of some advice I once heard: If you torture the data long enough, it will confess to anything.

Ha, ha, that is great!

[swampboots]

New data followed by massive insider buying and elite Bio's offering attaching validating "help", usually sharpens the data veracity.

[DewDiligence]

That’s a standout adage! What ICPT is doing looks like a variant on Zebra’s Law. I.e., ICPT has an approved drug (Ocaliva for PBC), but the approved indication is too narrow for the company to become profitable. Hence, ICPT continues to seek Ocaliva approval for NASH despite the drug’s utter unsuitability for that indication.